<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003588</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02277</org_study_id>
    <secondary_id>MDA-ID-97228</secondary_id>
    <secondary_id>NCI-T97-0111</secondary_id>
    <secondary_id>CDR0000066657</secondary_id>
    <nct_id>NCT00003588</nct_id>
  </id_info>
  <brief_title>Gene Therapy in Treating Patients With Ovarian Cancer</brief_title>
  <official_title>A Phase I Study of Ad-p53 (NSC# 683550) for Patients With Platinum- and Paclitaxel-Resistant Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of gene therapy in treating patients with ovarian&#xD;
      cancer that has not responded to previous treatment. Inserting the p53 gene into a person's&#xD;
      cancer cells may improve the body's ability to fight cancer or make the cancer cells more&#xD;
      sensitive to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated doses of adenovirus p53 in patients with platinum- and&#xD;
      paclitaxel-resistant ovarian epithelial cancer.&#xD;
&#xD;
      II. Determine the qualitative and quantitative toxic effects of this regimen in these&#xD;
      patients.&#xD;
&#xD;
      III. Document the observed anti-tumor activity of this regimen in these patients.&#xD;
&#xD;
      IV. Evaluate the biological endpoints (e.g., induction of apoptosis, p53 expression) of this&#xD;
      regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Patients undergo laparoscopy for p53 assessment and catheter placement. Patients receive&#xD;
      daily intraperitoneal injections of adenovirus p53 (Ad-p53) for 5 days every 3 weeks.&#xD;
      Treatment is repeated every 21 days in the absence of disease progression or unacceptable&#xD;
      toxicity. Cohorts of 3-6 patients each are treated at each dose level of Ad-p53. The maximum&#xD;
      tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose&#xD;
      limiting toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <primary_completion_date type="Actual">March 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo laparoscopy for p53 assessment and catheter placement. Patients receive daily intraperitoneal injections of adenovirus p53 (Ad-p53) for 5 days every 3 weeks. Treatment is repeated every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each are treated at each dose level of Ad-p53. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad5CMV-p53 gene</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic surgery</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic ovarian epithelial cancer that is platinum- and&#xD;
             paclitaxel resistant as defined by: Disease progression while on first-line regimen&#xD;
             containing both a platinum drug and paclitaxel OR Tumor progression within 6 months of&#xD;
             completion of platinum-based therapy (either as first- or second-line) or&#xD;
             paclitaxel-based therapy (either as first- or second-line)&#xD;
&#xD;
          -  Refractory or recurrent ovarian epithelial cancer as defined by: Lesions of any&#xD;
             diameter&#xD;
&#xD;
          -  Nonmeasurable disease (with CA-125 at least 35)&#xD;
&#xD;
          -  Ascites and/or pleural effusions allowed&#xD;
&#xD;
          -  No borderline or low malignant potential tumors&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Age: 18 and over&#xD;
&#xD;
          -  Performance status: Zubrod 0-2&#xD;
&#xD;
          -  Life expectancy: At least 12 weeks&#xD;
&#xD;
          -  WBC at least 3,000/mm3&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL PT/PTT normal&#xD;
&#xD;
          -  Creatinine no greater than 1.4 mg/dL&#xD;
&#xD;
          -  No active, unresolved upper respiratory infections&#xD;
&#xD;
          -  Not HIV positive&#xD;
&#xD;
          -  At least 5 years since prior malignancy, except nonmelanomatous skin cancer&#xD;
&#xD;
          -  Willing and able to undergo placement of Tenckhoff catheter in the peritoneal cavity&#xD;
             for sampling of ascites or peritoneal fluid&#xD;
&#xD;
          -  No concurrent serious medical illness&#xD;
&#xD;
          -  No untreated gastrointestinal obstruction&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  May have failed an unlimited number of prior chemotherapy regimens&#xD;
&#xD;
          -  At least 30 days since prior chemotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the pelvis or abdomen&#xD;
&#xD;
          -  Eligible for laparoscopy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith K. Wolf, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2002</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2004</study_first_posted>
  <last_update_submitted>February 7, 2013</last_update_submitted>
  <last_update_submitted_qc>February 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

